Fig. 6: TSA suppresses chemoresistance through CHFR.
From: CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1
a CHFR was stably knocked down in LM2 cells and treated with or without 0.6 μM TSA and immunoblotted with the CHFR and β-actin antibodies. b, c Scramble and sh-CHFR stable LM2 cells as described in a were co-treated with 0.6 μM TSA and the chemotherapy drugs 5-FU (b) or paclitaxel (c) for 36 h. After fixing with 10% methanol, the cells were then stained with 1:1000 crystal violet. d, e Scramble and sh-CHFR stable MDA-MB-231 cells were treated and analyzed as described in b, c. f LM2 cells that stably knocked down CHFR were rescued with or without MYC-CHFR and immunoblotted with the FASN, ZEB1, MYC, and β-actin antibodies. Significance of scramble versus sh-CHFR is shown. n = 3 wells per group. Data in b–e are the mean of biological replicates from a representative experiment, and error bars indicate s.e.m. Statistical significance was determined by a two-tailed, unpaired Student’s t test. The experiments were repeated three times.
